Your child's rages have a shape you can set a clock by, somebody has used the word bipolar, and the internet has offered you a diagnosis that never lets go and a list of medications with weight-gain warnings. There is a lot of research on exactly this question, and most of it is more reassuring — and more specific — than what you have been reading.

The short answer: yes, bipolar disorder occurs in children and adolescents, and it is less common than the internet implies. Across 19 studies and 56,103 young people, the pooled rate of bipolar I was 0.6 percent and of the whole bipolar spectrum 3.9 percent — and the same meta-analysis found that rates are not higher in the United States than elsewhere and are not increasing over time. The far more common thing, and the thing most often mistaken for it, is chronic non-episodic irritability. Three independent longitudinal studies found that chronic irritability in children predicts depression and anxiety in adulthood, not bipolar disorder: in the most direct test, 1.2 percent of chronically irritable young people had a manic or hypomanic episode on follow-up, against 62.4 percent of those with narrowly defined bipolar disorder. What separates the two is whether there are distinct episodes.¹ ² ³

How common it actually is

Definition Pooled prevalence Basis
Bipolar I 0.6% (95% CI 0.3–1.2) 19 studies, 56,103 young people¹
Bipolar spectrum, broadly defined 3.9% (95% CI 2.6–5.8) same¹

The six-fold gap between those two rows is entirely a matter of definition, not of biology. The meta-analysis identified the use of broad criteria as a predictor of higher reported prevalence, along with an older minimum age.¹ Any figure quoted without saying which definition it uses is close to meaningless.

Two findings from the same analysis are worth carrying, because they contradict the two things most often said in public:¹

"The updated meta-analysis confirms that rates of bipolar spectrum disorders are not higher in the United States than in other Western countries, nor are rates increasing over time."

"Newer studies were associated with lower rates."

The thing that is usually happening instead

A great many children referred with "mood swings" have chronic, non-episodic irritability: angry or grouchy most of the day, most days, punctuated by severe outbursts — but without discrete periods of elevated mood that begin and end.

That distinction was formalised because of what the follow-up studies found. The researcher whose work drove it described the problem: these are children "who have severe, nonepisodic irritability and the hyperarousal symptoms characteristic of mania but who lack the well-demarcated periods of elevated or irritable mood characteristic of bipolar disorder," and the longitudinal data "indicate that nonepisodic irritability in youths is common and is associated with an elevated risk for anxiety and unipolar depressive disorders, but not bipolar disorder, in adulthood."²

Three independent designs found the same thing:

  • A 20-year community follow-up of 631 people first assessed at a mean age of 13.8: irritability in adolescence predicted major depressive disorder (odds ratio 1.33), generalised anxiety disorder (1.72) and dysthymia (1.81) two decades later. "Youth irritability did not predict bipolar disorder or axis II disorders at follow-up."⁴
  • An epidemiological cohort of 1,420 children: those with severe mood dysregulation at a mean age of 10.6 were significantly more likely to have a depressive disorder in young adulthood (odds ratio 7.2).⁵
  • The most direct test. Following young people with severe mood dysregulation and young people with narrowly defined bipolar disorder: "Only one of 84 SMD subjects (1/84 [1.2%]…) experienced a (hypo-)manic or mixed episode during the study (median follow-up = 28.7 months). The frequency of such episodes was more than 50 times higher in those with narrowly defined BD (58/93 [62.4%])."³

This is not a reassurance that chronic irritability is harmless. The adult outcomes of childhood disruptive mood dysregulation disorder are poor: elevated rates of anxiety and depression, more likely to meet criteria for more than one adult disorder, "more likely to have adverse health outcomes, be impoverished, have reported police contact, and have low educational attainment as adults."⁶ It is a statement about which future is being predicted, and therefore which treatment to aim at.

And a fair caveat. The diagnosis created to capture chronic irritability is itself contested. In a clinical sample of 706 children, it "could not be delimited from oppositional defiant disorder and conduct disorder, had limited diagnostic stability, and was not associated with current, future-onset, or parental history of mood or anxiety disorders."⁷ The evidence that chronic irritability does not forecast bipolar disorder is strong; the evidence that it constitutes a valid stand-alone diagnosis is weaker.

Where subthreshold bipolar is different

Do not confuse chronic irritability with subthreshold bipolar disorder — young people with real but brief or incomplete episodes of elevated mood. Those two populations behave completely differently on follow-up.

In a study of 140 young people with subthreshold bipolar disorder followed for about five years, 45 percent converted to full bipolar I or II — 23 percent to bipolar I and 22 percent to bipolar II — with a median time to conversion of 58 weeks. The strongest predictor was a first- or second-degree family history of mania or hypomania.⁸

Set that beside the 1.2 percent conversion in the chronically irritable group.³ Same clinic corridors, entirely different trajectories. The variable that separates them is episodicity — whether there are distinct periods with a beginning and an end.

What the course looks like when it is bipolar disorder

The largest longitudinal study of young people with bipolar spectrum disorders, 413 participants aged 7 to 17, followed for four years:⁹

  • About 2.5 years after the index episode, 81.5 percent had fully recovered — and 1.5 years after that, 62.5 percent had a syndromal recurrence, particularly depression.
  • Participants were symptomatic during 60 percent of the follow-up period, mostly with subsyndromal depressive and mixed symptoms. "Manic symptomatology, especially syndromal, was less frequent."
  • Twenty-five percent of those with bipolar II converted to bipolar I; 38 percent of those with subthreshold bipolar converted to bipolar I or II.
  • Worse outcomes were associated with early onset, a subthreshold diagnosis, long illness duration, low socioeconomic status, and a family history of mood disorders.

The pattern is the adult pattern in miniature: recovery is the norm, recurrence is common, and depression rather than mania is where the time goes.

How it should be diagnosed

The UK's guideline is the most explicit text available, and it sets a higher bar than the manual used in the United States — worth knowing before you quote it at an American clinician:¹⁰

1.11.4 "Diagnosis of bipolar disorder in children or young people should be made only after a period of intensive, prospective longitudinal monitoring by a healthcare professional or multidisciplinary team trained and experienced in the assessment, diagnosis and management of bipolar disorder in children and young people, and in collaboration with the child or young person's parents or carers."

1.11.5 "When diagnosing bipolar disorder in children or young people take account of the following: mania must be present; euphoria must be present on most days and for most of the time, for at least 7 days; irritability is not a core diagnostic criterion."

1.11.6 "Do not make a diagnosis of bipolar disorder in children or young people on the basis of depression with a family history of bipolar disorder but follow them up."

1.11.1 "Do not use questionnaires in primary care to identify bipolar disorder in children or young people."

1.11.7 When assessing, follow the adult assessment recommendations "but involve parents or carers routinely and take into account the child or young person's educational and social functioning."

The US manual is more permissive: irritable mood can satisfy the mania criterion there, with a higher threshold on the accompanying symptoms. American practice generally follows it. What both agree on is that there must be a distinct episode — a change from the child's usual state, with a beginning and an end.

Treatment, and what is actually approved

Medication. A network meta-analysis of 18 trials and 2,844 young people found that all six second-generation antipsychotics studied outperformed placebo for manic symptoms — risperidone (standardised mean difference −1.18), olanzapine (−0.77), aripiprazole (−0.67), quetiapine (−0.60), asenapine (−0.54), ziprasidone (−0.43) — "whereas no mood stabilizer outperformed placebo." The authors add the necessary counterweight: "their use must be carefully weighed against important side effects," with "more sedation, weight gain, and metabolic issues."¹¹

The largest head-to-head trial, 279 medication-naive children, found higher response with risperidone than with lithium (68.5 percent against 35.6 percent) or divalproex (68.5 against 24.0), with "increased weight gain, body mass index, and prolactin level" on risperidone.¹²

What holds a US approval for young people, verified against current labelling:¹³

Approved for pediatric bipolar I mania Age
Lithium 7 and older (acute and maintenance)
Risperidone 10–17
Aripiprazole 10–17
Quetiapine 10–17
Asenapine 10–17
Olanzapine 13–17
Approved for pediatric bipolar depression Age
Lurasidone 10–17, monotherapy
Olanzapine–fluoxetine combination 10–17

Not approved in young people: ziprasidone (studied, but "the data were insufficient to fully assess the safety"), divalproex, lamotrigine and carbamazepine — none of which has a pediatric bipolar indication, and none of which beat placebo for youth mania in the network meta-analysis.¹¹ ¹³ That is a striking gap between what is licensed and what is commonly prescribed.

One specific safety point. Valproate should not be offered to young people unless there is no other effective and tolerated treatment, and the regulators' language on use by anyone who can become pregnant is unusually strong: in the UK, "In women who take valproate while pregnant, around 1 in 9 babies (11%) will have a birth defect," and "about 3 or 4 children in every 10 may have problems with early childhood development."¹⁴ ¹⁵

Psychosocial treatment. Three randomised trials, all adjunctive to medication, all small, and all pointing at depression and family functioning rather than at mania:

  • Family-focused therapy for adolescents, 58 young people, 21 sessions over nine months: no difference in recovery from the index episode, but "patients in FFT-A recovered from their baseline depressive symptoms faster than patients in EC (hazard ratio, 1.85…; P = .04)" and "spent fewer weeks in depressive episodes." The authors: "To establish full recovery, FFT-A may need to be supplemented with systematic care interventions effective for mania symptoms."¹⁶
  • Child- and family-focused CBT, 69 children aged 7 to 13: better engagement, lower dropout, and reductions in parent-reported mania and in depression.¹⁷
  • Multi-family psychoeducational psychotherapy, 165 children aged 8 to 12 with major mood disorders: lower mood severity at follow-up than a waitlist — and the waitlist group improved similarly once they received it.¹⁸

None of these should be described as preventing episodes. What they reliably do is reduce depressive symptoms, improve family functioning, and keep families in treatment.

What to do as a parent

  • Ask for episodes, not moods. The question that matters is whether there have been distinct periods — days, not hours — of a clearly different state, with a beginning and an end, noticeable to other people. Write down the dates you can remember.
  • Track it before the appointment. A few weeks of daily notes on mood, sleep, energy and behaviour is worth more than any questionnaire, and the guideline expects longitudinal monitoring rather than a single assessment.¹⁰ The printable mood and sleep log →
  • Ask about the alternatives explicitly, including chronic irritability, ADHD, anxiety, trauma and depression. The last two are what irritability actually predicts.²
  • Ask what the medication is for and when it will be reviewed, and about metabolic monitoring if an antipsychotic is started. Weight and metabolic effects are the main trade-off in this age group.¹¹
  • Ask what the family component is. Every psychosocial trial in this area involved the family.
  • Know the California specifics on consent and confidentiality, which change with age. Consent and privacy for California teens → · What a therapist can tell your parents →
  • If a higher level of care is proposed, the questions to ask first are specific. Check a residential programme → · PHP and IOP access →
  • If your child refuses to go, that is a common starting point. When a teen refuses therapy →

Q&A

Q: Can children be diagnosed with bipolar disorder? A: Yes. Pooled prevalence is 0.6 percent for bipolar I and 3.9 percent for the broadly defined spectrum, and rates are neither higher in the United States nor rising over time.¹ The diagnosis requires distinct episodes, and guidelines ask for a period of prospective longitudinal monitoring rather than a single visit.¹⁰

Q: My child is irritable all the time. Is that bipolar disorder? A: Chronic, non-episodic irritability is not bipolar disorder, and on follow-up it predicts depression and anxiety rather than mania — 1.2 percent had a manic or hypomanic episode against 62.4 percent of young people with narrowly defined bipolar disorder.³ It still needs treating; it needs treating for what it predicts.

Q: What is the difference between that and "subthreshold" bipolar disorder? A: Episodicity. Young people with brief or incomplete episodes of elevated mood converted to full bipolar disorder at 45 percent over about five years.⁸ Young people with continuous irritability converted at 1.2 percent.³

Q: Will my child need medication for life? A: That is not answerable in advance. What the course data show is high rates of recovery from the index episode and high rates of recurrence afterwards, with most of the symptomatic time being depressive.⁹ Treatment decisions are reviewed, not fixed.

Q: Is lithium safe for a child? A: It holds a US approval from age 7 for acute mania and maintenance, and it requires regular blood-level, kidney, thyroid and calcium monitoring.¹³ Whether it is right for a particular child is a prescriber's decision; the monitoring is not optional.

Q: The school says it's behavioural. My doctor says it's mood. A: Both can be describing the same child. What settles it is a longitudinal record from more than one setting, which is exactly what the guideline asks for and what a school assessment can contribute. Request a school assessment →

Ready to find someone who assesses young people properly? Filter therapists by approach, schedule and payment route → · The full bipolar map → · Helping a young person who does not want help →

In crisis? Call or text 988 — free, 24/7.

Sources

  1. Van Meter A, Moreira ALR, Youngstrom E, "Updated meta-analysis of epidemiologic studies of pediatric bipolar disorder," Journal of Clinical Psychiatry 80(3), 2019, 18r12180 — 19 studies, 56,103 young people; "Weighted average prevalence of bipolar spectrum disorders was 3.9% (95% CI, 2.6%-5.8%)… The pooled rate of bipolar I was 0.6% (95% CI, 0.3%-1.2%)"; "rates of bipolar spectrum disorders are not higher in the United States than in other Western countries, nor are rates increasing over time" — doi.org.
  2. Leibenluft E, "Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths," American Journal of Psychiatry 168(2), 2011, 129–142 — "Longitudinal data in both clinical and community samples indicate that nonepisodic irritability in youths is common and is associated with an elevated risk for anxiety and unipolar depressive disorders, but not bipolar disorder, in adulthood" — pmc.ncbi.nlm.nih.gov.
  3. Stringaris A, Baroni A, Haimm C, et al., "Pediatric bipolar disorder versus severe mood dysregulation: risk for manic episodes on follow-up," Journal of the American Academy of Child and Adolescent Psychiatry 49(4), 2010, 397–405 — "Only one of 84 SMD subjects (1/84 [1.2%]; 95% confidence interval CI = 0.0003 to 0.064) experienced a (hypo-)manic or mixed episode during the study… The frequency of such episodes was more than 50 times higher in those with narrowly defined BD (58/93 [62.4%])" — pmc.ncbi.nlm.nih.gov.
  4. Stringaris A, Cohen P, Pine DS, Leibenluft E, "Adult outcomes of youth irritability: a 20-year prospective community-based study," American Journal of Psychiatry 166(9), 2009, 1048–1054 — 631 participants; odds ratios of 1.33 for major depressive disorder, 1.72 for generalised anxiety disorder and 1.81 for dysthymia; "Youth irritability did not predict bipolar disorder or axis II disorders at follow-up" — pmc.ncbi.nlm.nih.gov.
  5. Brotman MA, Schmajuk M, Rich BA, et al., "Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children," Biological Psychiatry 60(9), 2006, 991–997 — 1,420 children; "youth who met criteria for SMD in the first wave… were significantly more likely to be diagnosed with a depressive disorder (odds ratio 7.2, confidence interval 1.3-38.8, p = .02)" — doi.org.
  6. Copeland WE, Shanahan L, Egger H, Angold A, Costello EJ, "Adult diagnostic and functional outcomes of DSM-5 disruptive mood dysregulation disorder," American Journal of Psychiatry 171(6), 2014, 668–674 — "more likely to have adverse health outcomes, be impoverished, have reported police contact, and have low educational attainment as adults"; "The long-term prognosis of children with DMDD is one of pervasive impaired functioning" — pmc.ncbi.nlm.nih.gov.
  7. Axelson D, Findling RL, Fristad MA, et al., "Examining the proposed disruptive mood dysregulation disorder diagnosis in children in the Longitudinal Assessment of Manic Symptoms study," Journal of Clinical Psychiatry 73(10), 2012, 1342–1350 — 706 children; "DMDD could not be delimited from oppositional defiant disorder and conduct disorder, had limited diagnostic stability, and was not associated with current, future-onset, or parental history of mood or anxiety disorders" — pmc.ncbi.nlm.nih.gov.
  8. Axelson DA, Birmaher B, Strober MA, et al., "Course of subthreshold bipolar disorder in youth: diagnostic progression from bipolar disorder not otherwise specified," Journal of the American Academy of Child and Adolescent Psychiatry 50(10), 2011, 1001–1016 — 140 young people; "Diagnostic conversion to BP-I or BP-II occurred in 63 subjects (45%)… Median time from intake to conversion was 58 weeks. First- or second-degree family history of mania or hypomania was the strongest baseline predictor" — pmc.ncbi.nlm.nih.gov.
  9. Birmaher B, Axelson D, Goldstein B, et al., "Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study," American Journal of Psychiatry 166(7), 2009, 795–804 — 413 young people; "81.5% of the participants had fully recovered, but 1.5 years later 62.5% had a syndromal recurrence"; symptomatic 60% of the follow-up period; conversion figures; predictors of poorer outcome — pmc.ncbi.nlm.nih.gov.
  10. National Institute for Health and Care Excellence, "Bipolar disorder: assessment and management," clinical guideline CG185, recommendations 1.11.1 to 1.11.7 — nice.org.uk.
  11. Vita G, Nöhles VB, Ostuzzi G, et al., "Systematic review and network meta-analysis: efficacy and safety of antipsychotics vs antiepileptics or lithium for acute mania in children and adolescents," Journal of the American Academy of Child and Adolescent Psychiatry 64(2), 2025, 143–157 — 18 studies, 2,844 participants; the standardised mean differences by drug; "whereas no mood stabilizer outperformed placebo"; "their use must be carefully weighed against important side effects" — doi.org.
  12. Geller B, Luby JL, Joshi P, et al., "A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents," Archives of General Psychiatry 69(5), 2012, 515–528 — 279 medication-naive participants; "Higher response rates occurred with risperidone vs lithium (68.5% vs 35.6%…) and vs divalproex sodium (68.5% vs 24.0%…)"; "Increased weight gain, body mass index, and prolactin level occurred with risperidone" — pmc.ncbi.nlm.nih.gov.
  13. US Food and Drug Administration, current prescribing information retrieved via the openFDA drug label API — pediatric bipolar indications for lithium carbonate (7 and older), RISPERDAL, ABILIFY, SEROQUEL, SAPHRIS and olanzapine (mania), and LATUDA and olanzapine–fluoxetine (bipolar depression, 10–17); GEODON: "the data were insufficient to fully assess the safety of Geodon in pediatric patients"; no pediatric bipolar indication for divalproex, lamotrigine or carbamazepine — open.fda.gov.
  14. National Institute for Health and Care Excellence, clinical guideline CG185, recommendation 1.11.11 — "Do not offer valproate to young people unless there is no other effective and tolerated treatment" — nice.org.uk.
  15. Medicines and Healthcare products Regulatory Agency, "Valproate use by women and girls" — "In women who take valproate while pregnant, around 1 in 9 babies (11%) will have a birth defect"; "about 3 or 4 children in every 10 may have problems with early childhood development" — gov.uk; US Food and Drug Administration, DEPAKOTE prescribing information, boxed warning on fetal risk — open.fda.gov.
  16. Miklowitz DJ, Axelson DA, Birmaher B, et al., "Family-focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial," Archives of General Psychiatry 65(9), 2008, 1053–1061 — 58 adolescents; "patients in FFT-A recovered from their baseline depressive symptoms faster than patients in EC (hazard ratio, 1.85; 95% confidence interval, 1.04-3.29; P = .04)"; "To establish full recovery, FFT-A may need to be supplemented with systematic care interventions effective for mania symptoms" — pmc.ncbi.nlm.nih.gov.
  17. West AE, Weinstein SM, Peters AT, et al., "Child- and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: a randomized clinical trial," Journal of the American Academy of Child and Adolescent Psychiatry 53(11), 2014, 1168–1178 — 69 children; better attendance and retention, and reductions in parent-reported mania and in depression — pmc.ncbi.nlm.nih.gov.
  18. Fristad MA, Verducci JS, Walters K, Young ME, "Impact of multifamily psychoeducational psychotherapy in treating children aged 8 to 12 years with mood disorders," Archives of General Psychiatry 66(9), 2009, 1013–1021 — 165 children with major mood disorders, 70 percent bipolar; "The WLC group showed a similar decrease in MSI scores 1 year later, when also following their treatment" — doi.org.

Paid for by participating therapists. Inclusion is computed from availability data — never purchased. No ads, no data sold.